{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=40", "query": { "intervention": "Protein Control", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 3499, "total_pages": 350, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T13:41:43.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01804829", "title": "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Infection", "Viruses", "Hepatocellular Carcinoma", "Hepatitis, Viral, Human", "Liver Cirrhosis" ], "interventions": [ { "name": "Civacir® 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biotest Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2013-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 23, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804829" }, { "nct_id": "NCT00296296", "title": "Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplant", "Diabetes Mellitus, Type 2", "Diabetic Nephropathy" ], "interventions": [ { "name": "Cyclosporin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "'Diabetes Education / Management'", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 29, "start_date": "2005-06", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296296" }, { "nct_id": "NCT00000762", "title": "A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Month to 18 Years" }, "enrollment_count": 72, "start_date": null, "completion_date": "1996-02", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 33, "location_summary": "Long Beach, California • Los Angeles, California • Oakland, California + 21 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000762" }, { "nct_id": "NCT00549770", "title": "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "AHU377", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1334, "start_date": "2007-09", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549770" }, { "nct_id": "NCT06143956", "title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "LY3305677", "type": "DRUG" }, { "name": "LY3841136", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" }, { "name": "LY3549492", "type": "DRUG" }, { "name": "LY3532226", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1481, "start_date": "2023-11-17", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 49, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06143956" }, { "nct_id": "NCT02415556", "title": "Memory Aid by Intranasal Insulin in Diabetes (MemAID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Regular Human Insulin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 289, "start_date": "2015-10-06", "completion_date": "2020-05-31", "has_results": true, "last_update_posted_date": "2022-05-19", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415556" }, { "nct_id": "NCT03446456", "title": "Vasopressin and Pain Perception in the Brain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Arginine vasopressin", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Observational learning", "type": "BEHAVIORAL" }, { "name": "fMRI data aquisition", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-09-17", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446456" }, { "nct_id": "NCT06379724", "title": "Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Burns", "Skin Graft Complications" ], "interventions": [ { "name": "Tranexamic acid", "type": "DRUG" }, { "name": "Thrombin JMI", "type": "DRUG" }, { "name": "skin graft", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2024-07-11", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06379724" }, { "nct_id": "NCT03276741", "title": "Oral Intake During Labor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Labor Complication", "Food Aspiration", "Complication of Anesthesia", "Satisfaction" ], "interventions": [ { "name": "gastric soft/bland diet", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "David Grant U.S. Air Force Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 126, "start_date": "2017-09-29", "completion_date": "2020-01-11", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 1, "location_summary": "Travis Air Force Base, California", "locations": [ { "city": "Travis Air Force Base", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03276741" }, { "nct_id": "NCT05501054", "title": "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ciforadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-02-09", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-29T13:41:43.836Z", "location_count": 3, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501054" } ] }